HGEN · Humanigen, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $221.0K | - | $221.0K | $1.04M | $1.04M | - | $1.04M | $1.04M | $486.0K | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $737.0K | - | $18.93M | $26.44M | $17.22M | - | $60.81M | $63.01M | $59.93M | - |
| SG&A | $3.72M | - | $4.01M | $3.95M | $4.34M | - | $6.20M | $8.08M | $4.95M | - |
| Total Operating Expenses | $4.46M | - | $22.94M | $30.39M | $21.57M | - | $67.02M | $71.09M | $64.88M | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($4.24M) | - | ($22.72M) | ($29.35M) | ($20.53M) | - | ($65.98M) | ($70.05M) | ($64.40M) | - |
| Interest Expense | $18.0K | - | $1.30M | $768.0K | $734.0K | - | $751.0K | $746.0K | $19.0K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($4.18M) | - | ($23.69M) | ($30.15M) | ($21.28M) | - | ($66.74M) | ($70.80M) | ($65.57M) | - |
| EPS - Basic | ($0.04) | - | ($1.12) | ($0.43) | ($0.32) | - | - | - | - | - |
| EPS - Diluted | ($0.32) | - | ($1.12) | ($0.43) | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.10M | $10.15M | $24.73M | $47.05M | $68.95M | $70.02M | $76.50M | $120.54M | $92.89M | $67.74M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $38.39M | $40.52M | $53.34M | $56.66M | $47.87M | $44.70M | $45.96M | $37.24M | $43.41M | $13.08M |
| Current Assets | $5.03M | $11.11M | $25.88M | $49.36M | $71.23M | $70.97M | $77.85M | $121.64M | $98.76M | $68.21M |
| Total Assets | $5.12M | $11.20M | $25.97M | $49.45M | $71.33M | $71.06M | $77.94M | $121.73M | $98.85M | $68.30M |
| Current Liabilities | $53.30M | $56.19M | $76.39M | $76.99M | $71.18M | $68.72M | $68.71M | $50.31M | $53.26M | $20.41M |
| Long-term Debt | - | - | - | $22.55M | $25.19M | $25.01M | $24.82M | $24.63M | $24.44M | - |
| Total Liabilities | $54.84M | $57.96M | $78.37M | $99.54M | $96.37M | $94.75M | $95.58M | $78.03M | $81.83M | $22.76M |
| Stockholders' Equity | ($49.73M) | ($46.77M) | ($52.41M) | ($50.09M) | ($25.05M) | ($23.69M) | ($17.64M) | $43.70M | $17.02M | $45.55M |
| Retained Earnings | ($685.99M) | ($681.81M) | ($686.20M) | ($662.51M) | ($632.36M) | ($611.08M) | ($577.54M) | ($510.80M) | ($440.00M) | ($374.43M) |
Cash Flow
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($7.06M) | - | - | - | ($19.44M) | - | - | - | ($35.82M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | $18.37M | - | - | - | $60.98M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -1916.3% | - | -10281.0% | -2833.1% | -1981.6% | - | -6368.6% | -6761.8% | -13250.2% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | -1892.3% | - | -10720.8% | -2910.1% | -2053.9% | - | -6442.0% | -6834.3% | -13491.2% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 333.5% | - | 8565.2% | 2551.9% | 1662.2% | - | 5869.8% | 6082.2% | 12332.1% | - |
| SG&A / Revenue | 1682.8% | - | 1815.8% | 381.2% | 419.4% | - | 598.8% | 779.5% | 1018.1% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -81.7% | - | -91.2% | -61.0% | -29.8% | - | -85.6% | -58.2% | -66.3% | - |
| Return on equity | 8.4% | - | 45.2% | 60.2% | 84.9% | - | 378.3% | -162.0% | -385.2% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.09 | 0.20 | 0.34 | 0.64 | 1.00 | 1.03 | 1.13 | 2.42 | 1.85 | 3.34 |
| Quick ratio | 0.09 | 0.20 | 0.34 | 0.64 | 1.00 | 1.03 | 1.13 | 2.42 | 1.85 | 3.34 |
| Cash ratio | 0.06 | 0.18 | 0.32 | 0.61 | 0.97 | 1.02 | 1.11 | 2.40 | 1.74 | 3.32 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | -0.45 | -1.01 | -1.06 | -1.41 | 0.56 | 1.44 | - |
| Debt / Assets | - | - | - | 0.46 | 0.35 | 0.35 | 0.32 | 0.20 | 0.25 | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -235.3x | - | -17.5x | -38.2x | -28.0x | - | -87.9x | -93.9x | -3389.3x | - |
| Equity multiplier | -0.10 | -0.24 | -0.50 | -0.99 | -2.85 | -3.00 | -4.42 | 2.79 | 5.81 | 1.50 |
| Liabilities / Assets | 10.72 | 5.18 | 3.02 | 2.01 | 1.35 | 1.33 | 1.23 | 0.64 | 0.83 | 0.33 |
| Efficiency | ||||||||||
| Asset turnover | 0.04 | - | 0.01 | 0.02 | 0.01 | - | 0.01 | 0.01 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -78.7% | - | -78.7% | 0.0% | 113.2% | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 79.4% | - | 65.6% | 58.1% | 68.1% | - | -114.6% | -203.3% | -3030.6% | - |
| Net income growth (YoY) | 80.3% | - | 64.5% | 57.4% | 67.5% | - | -117.0% | -194.7% | -2557.8% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -98.5% | -97.4% | -197.0% | - | - | - | - | 38.3% | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing HUMANIGEN against the 5 most active filers in the same SIC group.